Reolysin is a serotype 3 Dearing strain (T3D) of reovirus that replicates and induces programmed tumor cell death in RAS-activated tumor cells.
| SparkCures ID | 119 |
|---|---|
| Developed By | Oncolytics Biotech Inc. |
| Generic Name | Reolysin |
| Additional Names | Wild-type Reovirus |
| Treatment Classifications |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.